Haisco Pharmaceutical Group Co. Ltd. has synthesized poly(ADP-ribose) polymerase 1 (PARP-1; ARTD1) inhibitors reported to be useful for the treatment of cancer.
Ningbo Newbay Medical Technology Co. Ltd. has identified poly(ADP-ribose) polymerase 1 (PARP-1) inhibitors reported to be useful for the treatment of cancer.
Drawn to the potential for improved selectivity and safety profiles of PARP-1-specific inhibitors over their first-generation counterparts, Merck KGaA signed an exclusive, worldwide license deal with Jiangsu Hengrui Pharmaceuticals Co. Ltd. worth up to €1.4 billion (US$1.5 billion) to gain access to the latter’s next-generation poly (ADP-ribose) polymerase (PARP)-1 inhibitor, HRS-1167.
Drawn to the potential for improved selectivity and safety profiles of PARP-1-specific inhibitors over their first-generation counterparts, Merck KGaA signed an exclusive, worldwide license deal with Jiangsu Hengrui Pharmaceuticals Co. Ltd. worth up to €1.4 billion (US$1.5 billion) to gain access to the latter’s next-generation poly (ADP-ribose) polymerase (PARP)-1 inhibitor, HRS-1167.
Slap Pharmaceuticals LLC have identified new poly(ADP-ribose) polymerase 1 (PARP-1; ARTD1) inhibitors reported to be useful for the treatment of cancer.
Eikon Therapeutics Inc. has received IND clearance from the FDA to initiate phase I studies with IMP-1734, a highly selective poly(ADP-ribose) polymerase 1 (PARP-1) inhibitor developed in partnership with Impact Therapeutics Inc.
Wigen Biomedicine Technology (Shanghai) Co. Ltd. has synthesized compounds acting as poly(ADP-ribose) polymerase (PARP; ARTD) inhibitors, preferably PARP-1, reported to be useful for the treatment of cancer.
